Subscribe to Newsletter

Standards & Regulation

Business & Regulation Standards & Regulation

Chemistry and Humility

| Rob Coker | 3 min read

Countries that struggled to acquire COVID-19 vaccines have not forgotten the inequity, and are reminding pharma giants that they shouldn’t either

Business & Regulation Standards & Regulation

The Underworld of Counterfeit Fentanyl

| Jamie Irvine | 6 min read

A deep dive into the dangers of fentanyl entering the US supply chain – and the importance of the Drug Supply Chain Security Act

Manufacture Advanced Medicine

The World’s First CRISPR-Based Therapeutic Approval

| Stephanie Vine | 3 min read

It’s official: CRISPR medicines are here as UK authorizes exa-cel.

Business & Regulation Standards & Regulation

Nowhere to Hide

| Rob Coker | 2 min read

Never underestimate the meticulousness with which authorities operate or the standards that businesses are expected to adhere to.

Business & Regulation Standards & Regulation

FDA Warning Letters: September 2023 Edition

| Stephanie Vine | 4 min read

A look at cGMP deviations in recent warning letters, including manufacturing conducted in corridors and equipment uncleaned for 14 years.

Manufacture Process Control

Rent to Reduce

| Stephen Harding | 3 min read

Is renting material handling equipment the best way to help manufacturers tackle waste?

Manufacture Small Molecules

Making Your Mark

| Jim Gastle, Grant Peters | 4 min read

US-based law and patenting experts offer their thoughts on IP protection in the digital age

Manufacture Small Molecules

The Contaminated Childrens’ Cough Syrup Scandal

| Stephanie Vine | 4 min read

I explore recent cases of pediatric cough medicines contaminated with diethylene glycol.

Business & Regulation Standards & Regulation

Why Are Some Medicines Linked to Suicide?

| Stephanie Vine | 3 min read

The EMA is reviewing whether certain Novo Nordisk drugs are linked to suicidal thoughts

Discovery & Development Drug Discovery

A Call to Arms for Antimicrobial Resistance

| Peter Jackson | 13 min read

Investment into new antimicrobial therapies has been lacking for decades – and now we’re now paying the price.

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register